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 Abstract 
 Anti-hepatitis C virus (HCV) antibody seropositivity is independently associated with poor prog-
nosis in hemodialysis (HD) patients. However, anti-HCV antibody cannot distinguish between 
patients with active infection and those who have recovered from infection. We therefore 
aimed in this study to examine the association of HCV core antigen (HCVcAg) seropositivity with 
mortality in HD patients. We first measured serum HCVcAg using an immunoradiometric assay 
and anti-HCV antibody in 405 patients on regular HD, and followed them for 104 months. There 
were 82 patients (20.2%) who had been positive for anti-HCV antibodies; 57 (69.5%) of these 
were positive for HCVcAg. During the follow-up, 29 patients were excluded, so we tested the 
association of HCVcAg seropositivity with all-cause, cardiovascular (CV) and non-CV mortalities 
in 376 patients. A total of 209 patients (55.6%) had expired during the observational period, 92 
out of them due to CV causes. After adjusting for comorbid parameters, HCVcAg was indepen-
dently associated with overall mortality (HR 1.61, 95% CI 1.05–2.47, p   !   0.05). HCV infection was 
significantly related to liver disease-related mortality. Past HCV infection also contributed to CV 
mortality (HR 2.63, 95% CI 1.27–5.45, p  !  0.01). In contrast, anti-HCV antibody and HCVcAg sero-
positivities did not associate with infectious disease-related and cancer-related (expect for he-
patocellular carcinoma) mortality. It follows from these findings that HCVcAg serology is associ-
ated with all-cause and CV mortality in HD patients.    Copyright © 2012 S. Karger AG, Basel 
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 Introduction 
  The prevalence of hepatitis C virus (HCV) infection is much higher in hemodialysis 
(HD) patients than in the general population. The estimated prevalence of HCV infection 
(i.e., anti-HCV antibody positive) in dialysis patients was approximately 8% in the USA   [1]  , 
5% in Germany   [2]   and 10% in Japan   [3]  . Standardized prevalence rates for anti-HCV anti-
body were 13-fold higher in men and 9-fold higher in women when compared with the pop-
ulation-based controls   [4]  . The incidence of new seroconversion of anti-HCV antibody oc-
curred in about 1.0% of dialysis patients during the 1-year follow-up   [3]  . Outbreaks of inci-
dent HCV infection were also reported in at least 7 outpatient HD units during 1998–2008 
in the USA   [5]  .
    HCV infection is usually diagnosed based on the detection of anti-HCV antibody, while 
it goes undetected in the first 4–6 weeks of infection (so-called ‘window period’). Furthermore, 
patients positive for anti-HCV antibody include both those who are actively infected and those 
who have recovered from infection. Kidney Disease Improving Global Outcomes (KDIGO) 
clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis 
C in chronic kidney disease   [6]   recommended the use of nucleic acid test (NAT) either based 
on qualitative HCV RNA detection or HCV RNA quantification in units in high-prevalent set-
tings. However, NAT is not suitable for routine screening as it is expensive and labor intensive.
    Recently, measurement of HCV core antigen (HCVcAg) became clinically available us-
ing an immunoradiometric assay (IRMA)  [7–10] . This test can detect total nucleocapsid core 
antigen whose sequence is highly conserved across HCV genotypes. The IRMA test has 
96.4% sensitivity and 100% specificity for qualitative HCV RNA detection in a community-
based general population   [7]  . In HD patients, this assay showed a sensitivity and specificity 
of 84 and 89%, respectively  [8] . These findings suggest that HCVcAg is applicable for clinical 
use as an alternative to NAT.
    The aim of the present study was to evaluate in detail the association of chronic HCV 
infection with long-term mortality in HD patients in detail. We measured serum anti-HCV 
antibody and HCVcAg at the same time, and tested which causes of mortality are more like-
ly to be associated with anti-HCV antibody and/or HCVcAg seropositivity in patients on 
maintenance HD.
  Patients  and  Methods 
 Patients 
  We first enrolled 405 patients who had been undergoing regular HD in the two dialysis 
centers (Maruyama Hospital and Maruyama Clinic, Hamamatsu, Japan) in June 2002. This 
study was approved by the Ethics Committee of the institution, and informed consent was 
obtained from the patients.
    All patients had been subjected to regular HD for 4–5 h three times per week at a blood 
flow rate of 180–250 ml/min. All patients used bicarbonate dialysate (30 mEq/l; Kindaly AF-
2P, Fuso, Osaka, Japan) at a dialysate flow rate of 500 ml/min. No bacteria or pyrogen was 
detected in the dialysate fluid obtained by reverse osmosis. Using an endotoxin removal fil-
ter, the endotoxin concentration in dialysate was below 0.050 EU/ml with a Limulus Ame-
bocyte Lysate assay (Wako Junyaku endotoxin measurement kit, Tokyo, Japan).
    Blood Sampling and Laboratory Examinations 
  Blood samples were drawn from the arterial site of the arteriovenous fistula at the start 
of a dialysis session after the 2-day interval. Serum electrolytes, urea nitrogen, creatinine, 78
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aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline-phosphatase 
(Al-p), lactate dehydrogenase (LDH), albumin, cholesterol and triglyceride were measured 
by standard laboratory techniques using an autoanalyzer. Serum ferritin was measured by 
the latex agglutination method. Intact parathyroid hormone (PTH) was determined by im-
munoradiometric assay. C-reactive protein (CRP) was measured by latex photometric im-
munoassay (Wako Junyaku, Tokyo, Japan). We evaluated AST to platelet count ratio index 
(APRI), a non-invasive and sensitive marker of liver fibrosis in HD patients positive for anti-
HCV antibodies   [11]  . An APRI   !  0.40 has proved accurately to identify HD patients with 
liver fibrosis of stage 0–1, while an APRI   6  0.95 can estimate the presence of significant fi-
brosis in the liver biopsy samples   [11]  .
    Anti-HCV antibody test was performed by chemiluminescent enzyme immunoassay 
(EIA) using a third-generation assay (Ortho-Clinical Diagnostics, Emeryville, Calif., USA). 
Serum HCVcAg was measured by using IRMA (Ortho HCV antigen IRMA test, Ortho-
Clinical Diagnostics). We also determined serum HCV RNA level by a quantitative RT-PCR 
assay kit (Amplicor GT HCV Monitor v2.0, Nippon Roche, Tokyo, Japan) in patients positive 
for anti-HCV antibody. The concentration of HCV RNA was expressed as KIU/ml, which 
ranges from 0.5 to 850 KIU/ml. Serum samples with  ! 0.5 KIU/ml of HCV RNA were judged 
as negative. We also measured serum     -fetoprotein (AFP) by a liquid phase-binding assay 
(Wako Junyaku, Osaka, Japan; normal range   !  10 ng/ml), protein-induced by vitamin K ab-
sence or antagonism (PIVKA-II) by an enzyme immunoassay with an anti-deoxycytidine 
triphosphate monoclonal antibody (Eisai Laboratory, Tokyo, Japan; normal range  ! 40 mAU/
ml) and malondialdehyde (MDA) by spectrophotometry using thiobarbituric acid reactant 
(SRL, Tokyo, Japan) in anti-HCV antibody-positive patients. 
  Follow-Up  Study 
  We followed 405 patients until February 2011 (for a total of 104 months). During the 
follow-up, information on kidney transplantation, hospital transfer, and survival prognosis 
was identified during outpatient follow-up visits or hospitalization in the two dialysis cen-
ters, by reviewing hospital records or by directly contacting the referring physicians.
  Statistical  Analysis 
  Values were expressed as means   8   SD. The     2   test was used for categorical variables in-
cluding gender and underlying kidney disease and seropositivity of anti-HCV antibody and 
HCVcAg. Differences between the two groups were analyzed by an unpaired Student t test 
following the analysis of variance.
    The primary outcome studied was overall mortality. Cardiovascular (CV), infectious 
disease-related, cancer-related [excluding hepatocellular carcinoma (HCC)], and liver dis-
ease-related mortalities were tested as a secondary outcome. Causes of CV death included 
the following: congestive heart failure (CHF), acute myocardial infarction (AMI), angina 
pectoris, cerebrovascular disease, ischemic intestinal diseases, peripheral artery disease 
(PAD), sudden death, fatal arrhythmia and other ischemic events. The causes of liver disease-
related mortality included HCC and liver cirrhosis.
    Survival rate was estimated using the Kaplan-Meier curves, and compared by using the 
log-rank test. Cox proportional hazards models were applied to calculate hazard ratio (HR) 
and adjusted survival curves for time to death, adjusting for age and gender (model 1), and 
further adjusting for DM, serum creatinine, albumin, phosphorous, total cholesterol, hemo-
globin, log-transformed CRP, log-transformed ferritin and intact PTH (model 2). Results of 
the Cox proportional hazards analysis were presented as HR and the 95% confidence interval 
(95% CI). A p value   !  0.05 was considered statistically significant. All statistical calculations 
were performed with StatView 5J software (SAS Institute, Cary, N.C., USA).79
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  R e s u l t s  
 Clinical  Profiles 
  The enrolled study population included 272 males and 133 females, with a mean age of 
62 (19–96) years. The mean time on HD was 126 months, with a range of 1–394 months. The 
underlying kidney diseases were chronic glomerulonephritis (n = 238), diabetic nephropathy 
(n = 76), polycystic kidney disease (n = 20), benign nephrosclerosis (n = 19), rapidly progres-
sive glomerulonephritis (n = 5), lupus nephritis (n = 2), others (n = 12) and unknown (n = 33).
    Prevalence of Seropositivities for Anti-HCV Antibody and HCVcAg 
  Table 1  shows the prevalence of anti-HCV antibody and HCVcAg according to 6 catego-
ries of age and 7 classifications of HD duration. The numbers of HD patients positive for 
anti-HCV antibody and HCVcAg were 82 (20.2%) and 57 (14.1%), respectively. There was no 
patient who was HCVcAg positive and HCV antibody negative.
    A higher rate for anti-HCV antibody and HCVcAg was found in age categories of 50–59 
and 60–69 years. Patients with HD vintage   1  15 years (especially   1  20 years) had increased 
rates for anti-HCV antibody and HCVcAg. 
    Comparison of Laboratory Data between Patients with and without HCVcAg 
    Table 2   presents clinical characteristics of HD patients with or without anti-HCV anti-
body and/or HCVcAg. HCVcAg values ranged from 26 to 35,400 fmol/l. Time on HD was 
significantly longer in patients with anti-HCV antibody than in those without (p   !   0.01). 
However, there was no difference in HD vintage between patients with HCVcAg (n = 57) and 
those without (n = 25). Serum AST and ALT were significantly higher in patients positive for 
HCVcAg than in those negative (p   !   0.01). The prevalence of ALT values   1  28 IU/l (upper 
normal limit for HD patients)   [12]   was significantly higher in patients positive for HCVcAg 
n Anti-HCV antibody 
positive, n (%)
HCVcAg 
positive, n (%)
Age-specific prevalence
Age group
 <40 years 14 1 (7.1) 0 (0)
40–49 years 44 8 (18.2) 6 (13.6)
50–59 years 89 24 (27.0) 20 (22.5)
60–69 years 123 32 (26.0) 23 (18.7)
70–79 years 90 15 (16.7) 7 (7.8)
≥80 years 45 2 (4.4) 1 (2.2)
Total 405 82 (20.2) 57 (14.1)
HD vintage-related prevalence
Time on HD, years
<1 30 1 (3.3) 1 (3.3)
1–2 58 7 (12.1) 4 (6.9)
3–4 66 9 (13.6) 6 (9.1)
5–9 90 10 (11.1) 5 (5.6)
10–14 44 4 (9.1) 3 (6.8)
15–19 41 9 (22.2) 7 (18.5)
≥20 66 42 (63.6) 32 (48.5)
Total 405 82 (21.0) 57 (14.1)
H  CV = Hepatitis C virus; HCVcAg = HCV core antigen.
Table 1. P  revalence of anti-HCV 
antibody and HCVcAg 
positivities80
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(28.1%) than in those negative for HCVcAg while positive for anti-HCV antibody (3.0%) and 
in those negative for both (2.5%; p   !   0.01). White blood cell and platelet counts were also 
significantly lower in patients with HCV core antigenemia when compared with those with-
out (p   !   0.05 and p   !   0.01, respectively).
    We measured serum HCV RNA in 69 out of 82 anti-HCV antibody-positive patients 
(  table 3  ). Serum HCV RNA was detectable in 44 of 46 patients (95.6%) who were positive for 
HCVcAg and in 4 of 23 negative patients (17.4%).
  In anti-HCV antibody-positive patients (n = 82), there was no difference in serum AFP, 
PIVKA-II and MDA between HCVcAg-positive and -negative patients (  table 3  ). In con-
trast, APRI was higher in patients with HCVcAg when compared with those without (p   !  
0.01).
Table 2. C  linical characteristics of HD patients with or without anti-HCV antibody and/or HCVcAg
Anti-HCV 
antibody (–)/
HCVcAg (–)
A  nti-HCV antibody (+) Anti-HCV 
antibody (+), 
HCVcAg (+) 
versus (–)
HCVcAg (  +) HCVcAg (–)
Patients, n 323 57 25
HCVcAg, fmol/l <20 26–35,400 <20
Age, years 64814 60886 4 811 0.14
HD vintage, months 102883 2328121** 1898124** 0.14
Male/female 219/114 42/15 16/9 0.60
Diabetes, % 19 16 29 0.39
Laboratory parameters
Creatinine, mg/dl 11.883.3 11.882.5 10.982.4 0.13
Urea nitrogen, mg/dl 73.4815.3 72.6814.5 68.3817.4 0.26
Calcium, mg/dl 9.280.9 9.681.0** 9.380.7 0.17
Phosphorous, mg/dl 5.881.6 6.081.2 5.681.7 0.19
AST, IU/l 14818 1989* 1388 <0.01
ALT, IU/l 11819 21810** 1084 <0.01
Al-p, IU/l 2588160 2838144 2698131 0.69
LDH, IU/l 320881 325862 340880 0.34
Total cholesterol, mg/dl 159834 143831** 149841 0.44
Triglyceride, mg/dl 121874 108868 128887 0.26
Albumin, g/dl 3.880.4 3.880.3 3.880.4 0.95
Intact PTH, pg/ml 3288339 4148481 2158177 <0.05
Ferritin, ng/ml 1788191 1678243 1428121 0.63
Fe, g/dl 57824 67829** 64822 0.59
TIBC, g/dl 233844 259842** 227837 <0.01
CRP, mg/l 5.7820.1 1.782.3 3.185.7 0.11
White blood cells, /l 6,16082,030 5,09081,690** 5,95081,410 <0.05
Hemoglobin, g/dl 10.481.1 10.881.6* 10.481.7 0.36
Platelets, !104/l 19.386.4 14.884.7** 19.586.7 <0.01
The  re was no patient who was HCVcAg positive but not HCV antibody negative. HCV = Hepatitis C 
virus; HCVcAg = HCV core antigen; HD = hemodialysis; AST = aspartate aminotransferase; ALT = ala-
nine aminotransferase; Al-p = alkaline-phosphatase; LDH = lactate dehydrogenase; PTH = parathyroid 
hormone; Fe = iron; TIBC = total iron binding capacity; CRP = C-reactive protein. ** p < 0.01 and * p < 
0.05 versus the group of anti-HCV antibody-negative and HCVcAg-negative patients.81
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    Clinical Outcomes during the 104-Month Follow-Up 
 Out of 405 patients, 23 patients had transferred to other dialysis institutes, and 6 patients 
also had received kidney transplantation during the follow-up. The prevalence of anti-HCV 
antibody seropositivity in these patients (24.1%) was almost identical to that in the total pa-
tients (20.2%). Thus, we tested the association of HCV seropositivity with survival prognosis 
in 376 patients (male/female = 260/116). The mean age was 64  8  13 (22–96) years with a me-
dian HD time of 82 months (range 1–378). There were 75 patients (19.9%) who had been 
positive for anti-HCV antibody and 52 of them also positive for HCVcAg. 
    During the follow-up, 209 (55.6%) of the patients had expired, 92 (44.0%) out of them 
due to CV causes. The causes of CV death were the following: CHF in 25, sudden death in 
19, cerebral infarction in 17, AMI in 9, intestinal ischemia in 7, cerebral bleeding in 6, ar-
rhythmia in 4, angina pectoris in 3, and other reasons in 2 cases. Non-CV causes consisted 
of infectious diseases in 43 (pneumonia 22, sepsis 14, others 7), malignancies in 20 (lung 
cancer 4, HCC 3, blood disorder-related malignancy 3, renal cell carcinoma 2, others 8), ure-
mia in 20, gastrointestinal bleeding in 6, chronic obstructive pulmonary disease in 6, liver 
cirrhosis in 4, other reasons in 6, and unknown reasons in 11 patients.
    Kaplan-Meier estimation revealed that there was no significant difference in the cumu-
lative mortality rate of total death in the patients positive for both anti-HCV antibody and 
HCVcAg (67.3%, n = 52) and those positive for anti-HCV antibody while negative for 
HCVcAg (69.6%, n = 23), when compared with those without anti-HCV antibody (53.5%,
n = 301; p = 0.16;   fig. 1  a). The crude mortality rates per 1,000 patient-years were 60.5 in
patients without anti-HCV antibody, 77.6 in those positive for anti-HCV antibody and
HCVcAg, and 80.2 in those only positive for anti-HCV antibody.
    CV mortality rate was significantly higher in the patients seropositive for anti-HCV an-
tibody but not for HCVcAg (43.5%) compared to those seropositive for both anti-HCV anti-
body and HCVcAg (30.8%) and those without anti-HCV antibody (21.9%; p   !   0.05;   fig. 1 b). 
The crude CV mortality rates per 1,000 patient-years were 25.3 in patients without anti-HCV 
antibody, 35.5 in those positive for anti-HCV antibody and HCVcAg, and 65.2 in those pos-
itive for anti-HCV antibody but not for HCVcAg. In contrast, no difference was found in 
infectious disease-related and malignancy-related (excluding HCC) mortality among the 3 
groups  ( fig. 1 c,  d).
  There were 7 patients who had expired due to liver disease-related complications during 
the follow-up (HCC 4, liver cirrhosis 3). Five out of them were positive for HCVcAg, while 
Table 3. C  omparison of HCV infection markers between anti-HCV antibody-positive patients with 
HCVcAg positivity and without
HCVcAg p value
positive negative
HCV RNA, kIU/ml 316.08218.2 2.585.5 <0.01
Positivity for HCV RNA (>0.5 kIU/ml) 44/46 (95.6%) 4/23 (17.4%) <0.01
AFP, ng/ml 3.684.2 2.481.4 0.17
PIVKA-II, mAU/ml 18861 8 87 0.92
MDA, mol/l 2.880.6 2.680.5 0.18
APRI 1.5181.08 (0.25–6.13) 0.7880.63 (0.25–1.27) <0.01
H  CV = Hepatitis C virus; HCVcAg = HCV core antigen; AFP = -fetoprotein; PIVKA-II = protein-
induced by vitamin K absence or antagonism; MDA = malondialdehyde; APRI = AST to platelet count 
ratio index.82
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the others were negative for anti-HCV antibody. The crude mortality rates per 1,000 patient-
years were 0.8 in patients without anti-HCV antibody, while they increased to 11.1 in those 
both positive for anti-HCV antibody and HCVcAg. There was no patient who had expired 
in those positive for anti-HCV antibody but not for HCVcAg.
    Predictors of Total, CV and Non-CV Mortalities ( table 4 ) 
  Cox regression analysis adjusted for age and gender (model 1) revealed that patients 
positive for anti-HCV antibody had a significantly higher risk for all-cause (p   !   0.01), CV-
related (p   !   0.01) and liver disease-related mortality (p   !   0.01) when compared with those 
negative for anti-HCV antibody. Patients both positive for anti-HCV antibody and HCVcAg 
had a significantly higher risk for all-cause (p   !   0.01) and CV-related death (p = 0.03). Pa-
tients having anti-HCV antibody without HCVcAg had a significantly increased risk for CV 
death (p = 0.02).
    When further adjusted for co-morbid variables (model 2), anti-HCV antibody seroposi-
tivity was independently associated with a 1.61, 1.99, and 28.3-fold higher risk for total (p   !  
0.01), CV-related (p = 0.01) and liver disease-related death (p = 0.01), respectively. There was 
also a significantly greater risk for total mortality (p = 0.02) in patients with HCVcAg sero-
positivity. Anti-HCV antibody-positive patients without HCVcAg had a 2.63-fold higher risk 
for CV death (p   !   0.01).
  Fig. 1.  Associations between HCV seropositivity and all-cause, CV, infectious disease-related and cancer-
related (excluding HCC) mortality. There was no significant difference in all-cause mortality rate during 
the 104-month follow-up among the 3 groups. However, CV death was more prominent in patients posi-
tive for anti-HCV antibody but negative for HCVcAg. No difference was found in infectious disease-re-
lated and cancer-related (excluding HCC) mortality in the 3 groups. 83
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  Discussion 
 Recently, HCVcAg quantification assay has proved useful for an early diagnosis of HCV 
infection in community-based   [7]   and in dialysis populations   [8, 9]  . HCVcAg may be an al-
ternative to HCV RNA detection, since no subjects, who were negative for HCVcAg, were 
positive for HCV RNA in a large population-based cohort study   [4]  . In this study, based on 
the HCV RNA status as the gold standard, the sensitivity and the specificity of the IRMA 
assay were 95.6 and 82.6%, respectively. These values are comparable to a previous study   [8]  .
    In a general population, patients who have recovered from HCV infection do not de-
velop liver cirrhosis or HCC, while those with persistent HCV infection will develop serious 
complications over 20–30 years. So, information regarding HCV viremia is more important 
than that on the status of anti-HCV antibody. In this study, 57 (69.5%) out of 82 patients with 
anti-HCV antibody positivity had detectable HCVcAg values. Especially, anti-HCV anti-
body-positive patients with HD vintage  1 20 years had a high prevalence of HCVcAg (76.2%). 
A recent cohort study  [4]  also demonstrated that the seropositive rate for HCVcAg was 59.0% 
Table 4. C  ox hazard analysis for all-cause, CV and non-CV mortalities during the follow-up
Model 1 M  odel 2
HR (95% CI) p value HR (  95% CI) p value
All-cause mortality
Anti-HCV antibody (–) 1.0 1.0
Anti-HCV antibody (+) 1.63 (1.18–2.25) <0.01 1.68 (1.12–2.32) <0.01
HCVcAg (+) 1.77 (1.22–2.58) <0.01 1.61 (1.05–2.47) 0.02
HCVcAg (–) 1.40 (0.84–2.35) 0.20 1.61 (0.92–2.83) 0.10
CV mortality
Anti-HCV antibody (–) 1.0 1.0
Anti-HCV antibody (+) 1.95 (1.23–3.09) <0.01 1.99 (1.17–3.40) 0.01
HCVcAg (+) 1.83 (1.05–3.20) 0.03 1.66 (0.95–3.21) 0.14
HCVcAg (–) 2.15 (1.10–4.20) 0.02 2.63 (1.27–5.45) <0.01
Infectious disease-related mortality
Anti-HCV antibody (–) 1.0 1.0
Anti-HCV antibody (+) 1.90 (0.97–3.75) 0.06 1.91 (0.89–4.09) 0.10
HCVcAg (+) 1.71 (0.74–3.94) 0.21 1.75 (0.70–4.37) 0.23
HCVcAg (–) 2.25 (0.87–5.82) 0.09 2.22 (0.73–6.69) 0.16
Cancer-related mortality (excluding HCC)
Anti-HCV antibody (–) 1.0 1.0
Anti-HCV antibody (+) 1.95 (0.67–5.65) 0.22 2.29 (0.65–8.03) 0.19
HCVcAg (+) 2.51 (0.78–8.06) 0.12 3.00 (0.67–13.4) 0.15
HCVcAg (–) 1.06 (0.14–8.17) 0.96 1.43 (0.17–12.3) 0.75
Liver disease-related mortality
Anti-HCV antibody (–) 1.0 1.0
Anti-HCV antibody (+) 11.3 (2.17–58.3) <0.01 28.3 (2.10–282.1) 0.01
HCVcAg (+) ND ND
HCVcAg (–) ND ND
CV   = Cardiovascular; HCV = hepatitis C virus; HCVcAg = HCV core antigen; HR = hazards ratio; 
ND = not determined. We could not evaluate statistically whether HCVcAg seropositivity is related to 
liver disease-related mortality, since there was no death in the group positive for anti-HCV antibody while 
negative for HCVcAg.84
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in HD patients positive for anti-HCV antibody. The study also showed that the HCVcAg se-
ropositivity rate was 69.4% in patients with a longer dialysis period (  6  15 years). Taken to-
gether, these observations suggest that almost two thirds of anti-HCV antibody-positive HD 
patients have active HCV infection.
    There are several observational studies that have shown an independent and significant 
association of anti-HCV-positive serologic status and poor prognosis in HD patients  [12–20] . 
A recent meta-analysis of 7 cohorts including 11,589 HD patients estimated the overall ad-
justed relative risk of all-cause mortality to be 1.34 (95% CI 1.13–1.59) for anti-HCV anti-
body-positive patients relative to anti-HCV antibody negative counterparts   [21]  . A nation-
wide database in the USA   [17]   demonstrated that the HR of total death during the 3-year 
follow-up was 1.25 (95% CI 1.12–1.39) after adjusting for surrogates of the malnutrition-in-
flammation complex syndrome. Anti-HCV antibody seropositivity is also an independent 
predictor of a total mortality of 1 year with a relative risk of 1.37 (95% CI 1.15–1.62) in Japan 
 [18] . It has also been reported that HCV RNA positivity increased the risk of total death about 
1.8-fold (95% CI 1.01–3.14) when compared to non-viremic HD patients   [12]  . However, the 
main causes of death that increase mortality after chronic HCV infection remain to be fully 
determined.
  Recently, Ohsawa et al.  [20]  reported that HCVcAg seropositivity independently contrib-
utes to increased risks for all-cause death in prevalent HD patients during the 5-year follow-
up. In this study, we confirmed that HCV viremia detected by HCVcAg was significantly 
associated with all-cause mortality during the 104-month follow-up. In addition, the patients 
who had recovered from a past infection had a significantly higher risk for CV death. These 
findings suggest that HCV infection could increase all-cause and CV mortality in the long 
term. Kalantar-Zadeh et al.   [ 22 ]   also reported that anti-HCV antibody-positive patients 
younger than 65 years had a 1.8-fold higher risk for CV death. 
    Di Napoli et al.   [16]   first reported a greater risk for dying of liver or infectious causes in 
HCV-positive compared with HCV-negative HD patients in an observation period of 9 years 
(9.6 vs. 5.0%, p  !  0.01). A meta-analysis  [21] , however, disclosed that liver disease death alone 
was more frequent in anti-HCV antibody-positive patients than in anti-HCV antibody-neg-
ative patients. A recent study also failed to detect any association of HCVcAg seropositivity 
with infectious disease-related death  [20] . In the present study, we showed that the mortality 
rate due to liver disease was much higher in HCVcAg-positive patients. However, no asso-
ciation was found between HCV viremia and infectious disease-related and cancer-related 
mortality during the follow-up period, which is a comparable observation to that in the com-
munity-based cohort study   [23]  .
    HCV infection is associated with increases in inflammatory and oxidative stress mark-
ers in dialysis patients   [24, 25]  . In this study, however, there was no difference in serum CRP 
and MDA levels between HCVcAg-positive and HCVcAg-negative patients at study entry. In 
addition, demographic or clinical features were almost identical between patients with and 
without HCV viremia in anti-HCV antibody-positive patients. 
    There are several limitations to this study. First, our study was limited in size and selec-
tivity, comprising only 82 HCV-infected patients. Our study period (104 months) could be 
too short to attribute a direct effect of HCV seroconversion to death caused by liver disease. 
In addition, since we obviously studied a specific longevity group with a low prevalence of 
diabetes, our results may not be generally applicable. Second, we measured HCVcAg serol-
ogy only on study entry, so there is a possibility that we missed occult HCV infection (i.e., 
only detectable HCV RNA in the liver or peripheral blood mononuclear cells). HD therapy 
itself may also change HCVcAg positivity, since a single session decreases serum HCVcAg 
titers by 24.4%  [26] . Third, due to our insufficient database, we could not evaluate the impact 
of important risk factors such as blood pressure, body mass index, co-morbid conditions and 85
Nephron Extra 2012;2:76–86
 DOI:  10.1159/000337333 
  Published online: March 28, 2012 
EXTRA
  Kato et al.: HCVcAg Serology and Survival Prognosis 
www.karger.com/nne
  © 2012 S. Karger AG, Basel 
 References 
    1  Finelli L, Miller JT, Tokars JI, et al: National surveillance of dialysis-associated diseases in the Unit-
ed States. Semi Dial 2005;    18:   52–61. 
    2  Ross RS, Viazov S, Clauberg R, et al: Lack of de novo hepatitis C virus infections and absence of nos-
ocomial transmission of GB virus in a large cohort of German haemodialysis patients. J Viral Hepat 
2009;    16:   230–238. 
    3  Nakai S, Suzuki K, Masakane I, et al: Overview of regular dialysis treatment in Japan (as of 31 De-
cember 2008). Ther Apher Dial 2010;    14:   505–540. 
   4  Ohsawa M, Kato K, Itai K, et al: Standardized prevalence ratios for chronic hepatitis C virus infection 
among adult Japanese hemodialysis patients. J Epidemiol 2010;    20:   30–39. 
   5  Patel PR, Thompson ND, Kallen AJ, Arduino MJ: Epidemiology, surveillance, and prevention of 
hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis 2010;    56:   371–378. 
   6  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepa-
titis C in chronic kidney disease. Kidney Int 2008;    73(suppl  109):S1–S99. 
    7  Hayashi K, Hasuike S, Kusumoto K, et al: Usefulness of a new immuno-radiometric assay to detect 
hepatitis C core antigen in a community-based population. J Viral Hepat 2005;    12:   106–110. 
    8  Bouzgarrou N, Fodha I, Othman SB, et al: Evaluation of a total core antigen assay for the diagnosis 
of hepatitis C virus infection in haemodialysis patients. J Med Virol 2005;    77:   502–508. 
    9  Fabrizi F, Lunghi G, Aucella F, et al: Novel assay using total hepatitis C virus (HCC) core antigen 
quantification for diagnosis of HCV infection in dialysis patients. J Clin Microbiol 2005;    43:   414–420. 
  10  Medhi S, Potukuchi SK, Polipalli SK, et al: Diagnostic utility of hepatitis C virus core antigen in he-
modialysis patients. Clin Biochem 2008;    41:   447–452. 
  11  Schiavon LL, Shiavon JLN, Filho G, et al: Simple blood tests as noninvasive markers of liver fibrosis 
in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007;    46:   307–314. 
  12  Stehman-Breen CO, Enerson S, Gretch D, Johnson RJ: Risk of death among chronic dialysis patients 
infected with hepatitis C virus. Am J Kidney Dis 1998;    32:   629–634. 
 13  Pereira BJG, Natov SN, Bouthot BA, et al: Effect of hepatitis C infection and renal transplantation on 
survival in end-stage renal disease. Kidney Int 1998;    53:   1374–1381. 
  14  Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P: Risk of death and liver cirrhosis in 
anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001;    16:   1669–1674. 
socioeconomic status as explanatory variables. However, HCVcAg positivity is reported as 
an independent predictor of all-cause mortality even after the adjustment for these potent 
risk factors   [20]  . Finally, although the effect of interferon (IFN) therapy may have implica-
tions with respect to mortality rates in HCVcAg-positive patients, information on treatment 
was limited. In this study, 2 patients had been treated with IFN during the follow-up period, 
while treatment had shortly ceased due to adverse effects. 
    In conclusion, we show that HCVcAg seropositivity is associated with a greater risk for 
overall mortality during the 104-month follow-up. Chronic HCV infection was related to 
liver disease-related mortality. In addition, the patients who had recovered from past infec-
tion had a 2.63-fold higher risk for CV death. In contrast, HCVcAg was not associated with 
death due to infectious disease and cancer, except for HCC. These findings suggest that de-
tection of HCVcAg combined with anti-HCV antibody is useful in predicting long-term sur-
vival prognosis of persistent HCV infection in HD patients.
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